{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:41:15Z","timestamp":1775842875140,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T00:00:00Z","timestamp":1461974400000},"content-version":"vor","delay-in-days":120,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2016]]},"DOI":"10.6061\/clinics\/2016(04)11","type":"journal-article","created":{"date-parts":[[2016,4,18]],"date-time":"2016-04-18T22:34:06Z","timestamp":1461018846000},"page":"235-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities"],"prefix":"10.1016","volume":"71","author":[{"given":"Francisco Antonio Helfenstein","family":"Fonseca","sequence":"first","affiliation":[]},{"given":"Maria Cristina","family":"de Oliveira Izar","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"2","key":"10.6061\/clinics\/2016(04)11_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2013an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"issue":"6917","key":"10.6061\/clinics\/2016(04)11_bib2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"issue":"7407","key":"10.6061\/clinics\/2016(04)11_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nature11260","article-title":"Myocardial infarction accelerates atherosclerosis","volume":"487","author":"Dutta","year":"2012","journal-title":"Nature"},{"issue":"14","key":"10.6061\/clinics\/2016(04)11_bib4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"issue":"12","key":"10.6061\/clinics\/2016(04)11_bib5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"issue":"26","key":"10.6061\/clinics\/2016(04)11_bib6","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.6061\/clinics\/2016(04)11_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.6061\/clinics\/2016(04)11_bib8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/CIRCOUTCOMES.109.848473","volume":"2","author":"Ridker","year":"2009","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"10.6061\/clinics\/2016(04)11_bib9","first-page":"151","article-title":"2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult","volume":"29","author":"Anderson","year":"2013","journal-title":"Can J Cardiol"},{"issue":"25 Suppl 2","key":"10.6061\/clinics\/2016(04)11_bib10","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"issue":"14","key":"10.6061\/clinics\/2016(04)11_bib11","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"issue":"2","key":"10.6061\/clinics\/2016(04)11_bib12","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.amjcard.2010.03.018","article-title":"Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)","volume":"106","author":"Ridker","year":"2010","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.6061\/clinics\/2016(04)11_bib13","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","volume":"121","author":"Mora","year":"2010","journal-title":"Circulation"},{"issue":"9709","key":"10.6061\/clinics\/2016(04)11_bib14","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.6061\/clinics\/2016(04)11_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.atherosclerosis.2009.04.020","article-title":"C-reactive protein levels and risk of mortality from cardiovascular disease in Japanese: the JACC Study","volume":"207","author":"Iso","year":"2009","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.6061\/clinics\/2016(04)11_bib16","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1161\/ATVBAHA.107.157164","article-title":"High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama study","volume":"28","author":"Arima","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.6061\/clinics\/2016(04)11_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.004176","article-title":"Elevated circulating adipocyte-fatty acid binding protein levels predict incident cardiovascular events in a community-based cohort: a 12-year prospective study","volume":"2","author":"Chow","year":"2013","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.6061\/clinics\/2016(04)11_bib18","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/CIRCGENETICS.110.957431","article-title":"Ancestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk prediction","volume":"3","author":"Shah","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"key":"10.6061\/clinics\/2016(04)11_bib19","article-title":"Usefulness of C-reactive protein as a marker for prediction of future coronary events in the asian Indian population: Indian atherosclerosis research study","volume":"2010","author":"Rao","year":"2010","journal-title":"Int J Vasc Med"},{"issue":"4","key":"10.6061\/clinics\/2016(04)11_bib20","first-page":"427","article-title":"A comparison of cardiovascular disease risk factor biomarkers in African Americans and Yoruba Nigerians","volume":"18","author":"Deeg","year":"2008","journal-title":"Ethn Dis"},{"issue":"11","key":"10.6061\/clinics\/2016(04)11_bib21","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/sj.jhh.1002065","article-title":"Inflammation, obesity and cardiovascular function in African and Caucasian women from South Africa: the POWIRS study","volume":"20","author":"Schutte","year":"2006","journal-title":"J Hum Hypertens"},{"issue":"6","key":"10.6061\/clinics\/2016(04)11_bib22","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1373\/clinchem.2007.098996","article-title":"Ethnic differences in C-reactive protein concentrations","volume":"54","author":"Kelley-Hedgepeth","year":"2008","journal-title":"Clin Chem"},{"issue":"2","key":"10.6061\/clinics\/2016(04)11_bib23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ijcard.2011.11.034","article-title":"Association of novel biomarkers with future cardiovascular events is influenced by ethnicity: results from a multi-ethnic cohort","volume":"166","author":"Veeranna","year":"2013","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.6061\/clinics\/2016(04)11_bib24","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1373\/clinchem.2008.122093","article-title":"Implications of increased C-reactive protein for cardiovascular risk stratification in black and white men and women in the US","volume":"55","author":"Cushman","year":"2009","journal-title":"Clin Chem"},{"issue":"1","key":"10.6061\/clinics\/2016(04)11_bib25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-10-0277","article-title":"Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study","volume":"163","author":"Tabak","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.6061\/clinics\/2016(04)11_bib26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1464-5491.2011.03560.x","article-title":"C-reactive protein concentration predicts mortality in type 2 diabetes: the Diabetes Heart Study","volume":"29","author":"Cox","year":"2012","journal-title":"Diabet Med"},{"issue":"21","key":"10.6061\/clinics\/2016(04)11_bib27","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.6061\/clinics\/2016(04)11_bib28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ahj.2011.03.032","article-title":"Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial","volume":"162","author":"Albert","year":"2011","journal-title":"Am Heart J"},{"key":"10.6061\/clinics\/2016(04)11_bib29","first-page":"347","article-title":"The association between obesity, cardiometabolic disease biomarkers, and innate immunity-related inflammation in Canadian adults","volume":"5","author":"Da Costa","year":"2012","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"10.6061\/clinics\/2016(04)11_bib30","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/obr.12003","article-title":"Obesity and C-reactive protein in various populations: a systematic review and meta-analysis","volume":"14","author":"Choi","year":"2013","journal-title":"Obes Rev"},{"key":"10.6061\/clinics\/2016(04)11_bib31","author":"WHO Global Infobase"},{"issue":"3","key":"10.6061\/clinics\/2016(04)11_bib32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/dmrr.923","article-title":"Association between C-reactive protein and pre-diabetic status in a Chinese Han clinical population","volume":"25","author":"Lin","year":"2009","journal-title":"Diabetes Metab Res Rev"},{"key":"10.6061\/clinics\/2016(04)11_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1475-2840-10-51","article-title":"Association between fasting plasma glucose and high-sensitivity C-reactive protein: gender differences in a Japanese community-dwelling population","volume":"10","author":"Kawamoto","year":"2011","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.6061\/clinics\/2016(04)11_bib34","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1177\/193229681100500421","article-title":"High sensitivity C-reactive protein, tumor necrosis factor-alpha, interleukin-6, and vascular cell adhesion molecule-1 levels in Asian Indians with metabolic syndrome and insulin resistance (CURES-105)","volume":"5","author":"Indulekha","year":"2011","journal-title":"J Diabetes Sci Technol"},{"issue":"5","key":"10.6061\/clinics\/2016(04)11_bib35","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/00004872-200105000-00004","article-title":"Is C-reactive protein an independent risk factor for essential hypertension","volume":"19","author":"Bautista","year":"2001","journal-title":"J Hypertens"},{"issue":"4","key":"10.6061\/clinics\/2016(04)11_bib36","doi-asserted-by":"crossref","first-page":"804","DOI":"10.2337\/dc09-1679","article-title":"Inflammation and the incidence of type 2 diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"33","author":"Bertoni","year":"2010","journal-title":"Diabetes care"},{"issue":"4","key":"10.6061\/clinics\/2016(04)11_bib37","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/HJH.0b013e328326f801","article-title":"C-reactive protein implications in new-onset hypertension in a healthy population initially aged 65 years: the Proof study","volume":"27","author":"Dauphinot","year":"2009","journal-title":"J Hypertens"},{"issue":"10","key":"10.6061\/clinics\/2016(04)11_bib38","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1524-6175.2004.03577.x","article-title":"Elevation of C-reactive protein in people with prehypertension","volume":"6","author":"King","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"22","key":"10.6061\/clinics\/2016(04)11_bib39","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1001\/jama.290.22.2945","article-title":"C-reactive protein and the risk of developing hypertension","volume":"290","author":"Sesso","year":"2003","journal-title":"JAMA"},{"issue":"10","key":"10.6061\/clinics\/2016(04)11_bib40","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ajh.2011.119","article-title":"Lack of independent association between C-reactive protein and central aortic hemodynamics in black Africans with high risk of cardiovascular disease","volume":"24","author":"Redelinghuys","year":"2011","journal-title":"Am J Hypertens"},{"issue":"8","key":"10.6061\/clinics\/2016(04)11_bib41","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.amjhyper.2005.03.730","article-title":"C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community","volume":"18","author":"Kullo","year":"2005","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.6061\/clinics\/2016(04)11_bib42","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2004.11.019","article-title":"Association between serum C-reactive protein levels and pulse wave velocity: a population-based cross-sectional study in a general population","volume":"180","author":"Nagano","year":"2005","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.6061\/clinics\/2016(04)11_bib43","doi-asserted-by":"crossref","first-page":"78","DOI":"10.5830\/CVJA-2011-035","article-title":"The relationship between cortisol, C-reactive protein and hypertension in African and Causcasian women: the POWIRS study","volume":"23","author":"Tolmay","year":"2012","journal-title":"Cardiovasc J Afr"},{"key":"10.6061\/clinics\/2016(04)11_bib44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/5584_2014_6","article-title":"C-reactive protein and lipoprotein-associated phospholipase A2 in smokers and nonsmokers of the Ludwigshafen Risk and Cardiovascular Health study","volume":"832","author":"Kleber","year":"2015","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"10.6061\/clinics\/2016(04)11_bib45","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0002-9149(99)00491-9","article-title":"Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men","volume":"84","author":"Rohde","year":"1999","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.6061\/clinics\/2016(04)11_bib46","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0002-9149(02)02284-1","article-title":"Relation between markers of systemic vascular inflammation and smoking in women","volume":"89","author":"Bermudez","year":"2002","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.6061\/clinics\/2016(04)11_bib47","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jch.12047","article-title":"The impact of cigarette smoking on 24-hour blood pressure, inflammatory and hemostatic activity, and cardiovascular risk in Japanese hypertensive patients","volume":"15","author":"Yano","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"10.6061\/clinics\/2016(04)11_bib48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N Engl J med"},{"issue":"10","key":"10.6061\/clinics\/2016(04)11_bib49","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2005.02.080","article-title":"Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg\/dl and C-reactive protein <2 mg\/l: an analysis of the PROVE-IT TIMI-22 trial","volume":"45","author":"Ridker","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"10.6061\/clinics\/2016(04)11_bib50","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"9602","key":"10.6061\/clinics\/2016(04)11_bib51","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(07)61778-4","article-title":"Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths","volume":"370","author":"Lewington","year":"2007","journal-title":"Lancet (London, England)"},{"issue":"9493","key":"10.6061\/clinics\/2016(04)11_bib52","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"9753","key":"10.6061\/clinics\/2016(04)11_bib53","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"9607","key":"10.6061\/clinics\/2016(04)11_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"issue":"9841","key":"10.6061\/clinics\/2016(04)11_bib55","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"issue":"7347","key":"10.6061\/clinics\/2016(04)11_bib56","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.6061\/clinics\/2016(04)11_bib57","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/ije\/dyu027","article-title":"Cohort Profile: Longitudinal Study of Adult Health (ELSA-Brasil)","volume":"44","author":"Schmidt","year":"2015","journal-title":"International journal of epidemiology"},{"issue":"10","key":"10.6061\/clinics\/2016(04)11_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108426","article-title":"Life course socioeconomic position and C-reactive protein: mediating role of health-risk behaviors and metabolic alterations. The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)","volume":"9","author":"Camelo","year":"2014","journal-title":"PloS one"},{"issue":"17","key":"10.6061\/clinics\/2016(04)11_bib59","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/eurheartj\/eht022","article-title":"C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care","volume":"34","author":"Ridker","year":"2013","journal-title":"Eur Heart J"},{"issue":"9670","key":"10.6061\/clinics\/2016(04)11_bib60","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"issue":"8","key":"10.6061\/clinics\/2016(04)11_bib61","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jacc.2005.08.024","article-title":"Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J Am Coll Cariol"},{"issue":"4","key":"10.6061\/clinics\/2016(04)11_bib62","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2011.06.012","article-title":"Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"162","author":"Ridker","year":"2011","journal-title":"Am heart J"},{"issue":"2","key":"10.6061\/clinics\/2016(04)11_bib63","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1373\/clinchem.2008.120642","article-title":"Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study","volume":"55","author":"Glynn","year":"2009","journal-title":"Clin Chem"},{"key":"10.6061\/clinics\/2016(04)11_bib64","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ahj.2015.04.017","article-title":"Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality","volume":"170","author":"Parrinello","year":"2015","journal-title":"Am Heart J"},{"issue":"1","key":"10.6061\/clinics\/2016(04)11_bib65","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.atherosclerosis.2012.07.017","article-title":"Intraindividual variability of C-reactive protein: the Multi-Ehtnic Study of Atherosclerosis","volume":"224","author":"DeGoma","year":"2012","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.6061\/clinics\/2016(04)11_bib66","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4274\/jcrpe.2187","article-title":"Low-grade inflammation and increased arterial stiffness in Chinese youth and adolescents with newly-diagnosed Type 2 diabetes mellitus","volume":"7","author":"Li","year":"2015","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"0","key":"10.6061\/clinics\/2016(04)11_bib67","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.clinbiochem.2013.12.014","article-title":"High sensitivity C-reactive protein (Hs-CRP) remains highly stable in long-term archived human serum","volume":"47","author":"Doumatey","year":"2014","journal-title":"Clin Biochem"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222011152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593222011152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:58:37Z","timestamp":1761721117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593222011152"},"secondary":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_abstract&pid=S1807-59322016000400235&lng=en&nrm=iso","label":"SCIELO"},{"URL":"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4825196\/?report=classic","label":"PMC"}]},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"alternative-id":["S1807593222011152"],"URL":"https:\/\/doi.org\/10.6061\/clinics\/2016(04)11","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-Sensitivity C-Reactive Protein and Cardiovascular Disease Across Countries and Ethnicities","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.6061\/clinics\/2016(04)11","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 CLINICS. Published by Elsevier Spain","name":"copyright","label":"Copyright"}]}}